This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Soyon Hong
UK Dementia Research Institute at University College London, London, UK

Dr. Soyon Hong is a Group Leader at the UK Dementia Research Institute (UK DRI) at University College London (UCL). She received her PhD in Neuroscience in 2012 from Harvard University, after having trained with Dr Dennis Selkoe, and completed her post-doctoral fellowship at Boston Children’s Hospital and Harvard Medical School in 2018 in the lab of Dr Beth Stevens. While in this latter role, she conducted a study that was among the first to propose microglia as critical players in synaptic pathology in disease. In 2018, Dr Hong started her lab at the UK DRI, aiming to understand immune mechanisms of neural circuitry and function. Specifically, the lab studies how synapses are targeted in the adult brain for elimination. To that end, the lab recently discovered a role for perivascular cells in influencing microglia-synapse phagocytosis via SPP1/osteopontin in models of amyloidosis. The lab employs spatial and single-cell omics as well as functional studies in disease models to profile intercellular neuroimmune/neuroglial interactions and how they may confer region-specific synapse vulnerability in Alzheimer’s and Parkinson’s diseases.